Nuvectis Pharma, Inc. (NVCT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$20.05-4.02%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Nuvectis Pharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.253
Annual ending 2026-12-31
Revenue	—	2.96M
EPS	—	-1.043
Annual ending 2027-12-31
Revenue	—	26M
EPS	—	-1.152

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient funding to support operations into 2H 2027	The company secured $100 million in funding to support operations through the second half of 2027.	Intact	Funding falls short of supporting operations beyond mid-2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve earnings trajectory and reduce losses	A supporting condition in Nuvectis Pharma, Inc.'s published investment case. The stated target is EPS loss narrows or stabilizes near -$1.04 in FY26.	Under Pressure	EPS loss worsens beyond -$1.04 in FY26	Diluted EPS: $-0.30 per share FY2026-Q2; GAAP. Published target: EPS loss narrows or stabilizes near -$1.04 in FY26. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-0.3 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4a61897c-1278-47dc-b3f6-90a7ab78617a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Preliminary data readout from NXP900 Phase 1b study	Nuvectis Pharma aims to advance its NXP900 cancer drug with a key data readout expected in summer 2026.	Intact	Data readout is delayed beyond Q3 2026 or results are negative	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.15

$-1.05 → $-1.15 · observed estimates

FY2027 revenue$0.03B

$0.00B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.05	$0	5 / 5
2026-07-25	Unavailable	$26,001,000	4 / 5
2026-07-26	$-1.05	$0	5 / 5
2026-07-27	Unavailable	$26,001,000	4 / 5
2026-07-28	$-1.01	$0	5 / 5
2026-07-29	Unavailable	$26,001,000	4 / 5
2026-07-30	$-1.01	$0	5 / 5
2026-07-31	$-1.01	$0	5 / 5
2026-08-01	Unavailable	$26,001,000	4 / 5
2026-08-02	$-1.01	$0	5 / 5
2026-08-03	$-1.01	$0	5 / 5
2026-08-04	$-1.01	$0	5 / 5
2026-08-05	Unavailable	$26,001,000	4 / 5
2026-08-06	$-1.01	$0	5 / 5
2026-08-07	Unavailable	$26,001,000	4 / 5
2026-08-08	$-1.15	$0	5 / 5
2026-08-09	$-1.17	$0	5 / 5
2026-08-10	$-1.17	$0	5 / 5
2026-08-12	$-1.13	$0	5 / 5
2026-08-13	Unavailable	$26,001,000	4 / 5
2026-08-14	Unavailable	$26,001,000	4 / 5
2026-08-15	Unavailable	$26,001,000	4 / 5
2026-08-16	Unavailable	$26,001,000	4 / 5
2026-08-17	Unavailable	$26,001,000	4 / 5
2026-08-18	Unavailable	$26,001,000	4 / 5
2026-08-19	Unavailable	$26,001,000	4 / 5
2026-08-20	Unavailable	$26,001,000	4 / 5
2026-08-21	Unavailable	$26,001,000	4 / 5
2026-08-22	Unavailable	$26,001,000	4 / 5
2026-08-23	Unavailable	$26,001,000	4 / 5
2026-08-24	Unavailable	$26,001,000	4 / 5
2026-08-25	Unavailable	$26,001,000	4 / 6
2026-08-26	Unavailable	$26,001,000	4 / 6
2026-08-27	Unavailable	$26,001,000	4 / 6
2026-08-28	Unavailable	$26,001,000	4 / 6
2026-08-29	$-1.17	$26,001,000	5 / 6
2026-08-30	$-1.06	$26,001,000	5 / 6
2026-08-31	$-1.06	$26,001,000	5 / 6
2026-09-01	$-1.06	$26,001,000	5 / 6
2026-09-02	Unavailable	$26,001,000	4 / 5
2026-09-03	$-1.15	$26,001,000	5 / 6
2026-09-04	$-1.15	$26,001,000	5 / 6
2026-09-05	$-1.15	$26,001,000	5 / 6
2026-09-06	$-1.15	$26,001,000	5 / 6
2026-09-07	$-1.15	$26,001,000	5 / 6
2026-09-08	$-1.15	$26,001,000	5 / 6
2026-09-09	$-1.15	$26,001,000	5 / 6
2026-09-10	$-1.15	$26,001,000	5 / 6
2026-09-11	$-1.15	$26,001,000	5 / 6
2026-09-12	$-1.15	$26,001,000	5 / 6
2026-09-13	$-1.15	$26,001,000	5 / 6
2026-09-14	$-1.15	$26,001,000	5 / 6
2026-09-15	$-1.15	$26,001,000	5 / 6
2026-09-16	$-1.15	$26,001,000	5 / 6
2026-09-17	$-1.15	$26,001,000	5 / 6
2026-09-18	$-1.15	$26,001,000	5 / 6
2026-09-19	$-1.15	$26,001,000	5 / 6
2026-09-20	$-1.15	$26,001,000	5 / 6
2026-09-21	$-1.15	$26,001,000	5 / 6
2026-09-22	$-1.15	$26,001,000	5 / 6
2026-09-23	$-1.15	$26,001,000	5 / 6
2026-09-24	$-1.15	$26,001,000	5 / 6
2026-09-25	$-1.15	$26,001,000	5 / 6
2026-09-26	$-1.15	$26,001,000	5 / 6
2026-09-27	$-1.15	$26,001,000	5 / 6
2026-09-28	$-1.15	$26,001,000	5 / 6
2026-09-29	$-1.15	$26,001,000	5 / 6
2026-09-30	$-1.15	$26,001,000	5 / 6
2026-10-01	$-1.15	$26,001,000	5 / 6
2026-10-02	$-1.15	$26,001,000	5 / 6
2026-10-03	$-1.15	$26,001,000	5 / 6
2026-10-04	$-1.15	$26,001,000	5 / 6
2026-10-05	$-1.15	$26,001,000	5 / 6
2026-10-06	$-1.15	$26,001,000	5 / 6
2026-10-07	$-1.15	$26,001,000	5 / 6
2026-10-08	$-1.15	$26,001,000	5 / 6
2026-10-09	$-1.15	$26,001,000	5 / 6
2026-10-10	$-1.15	$26,001,000	5 / 6
2026-10-11	$-1.15	$26,001,000	5 / 6
2026-10-12	$-1.15	$26,001,000	5 / 6
2026-10-13	$-1.15	$26,001,000	5 / 6
2026-10-14	$-1.15	$26,001,000	5 / 6
2026-10-15	$-1.15	$26,001,000	5 / 6
2026-10-16	$-1.15	$26,001,000	5 / 6
2026-10-17	$-1.15	$26,001,000	5 / 6
2026-10-18	$-1.15	$26,001,000	5 / 6
2026-10-19	$-1.15	$26,001,000	5 / 6
2026-10-20	$-1.15	$26,001,000	5 / 6
2026-10-21	$-1.15	$26,001,000	5 / 6
2026-10-22	$-1.15	$26,001,000	5 / 6
2026-10-23	$-1.15	$26,001,000	5 / 6
2026-10-24	$-1.15	$26,001,000	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient funding to support operations into 2H 2027Direct metric needs a verified mapping
Improve earnings trajectory and reduce lossesPublished status: Under Pressure
Preliminary data readout from NXP900 Phase 1b studyDirect metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-36.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Nuvectis Pharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical development story, not an established earnings compounder. The thesis is in a watch state: management is advancing ciprocopan and expanding the pipeline, but recent financial performance trails its industry cohort.

What's priced into Nuvectis Pharma, Inc.

The evidence gives no valuation measure or clear account of what the market assumes, so whether NVCT is cheap, fair, or expensive versus peers cannot be assessed. No priced-in fragility gates fired, but that does not resolve the uncertainty around expectations.

What the fundamentals likely do

Near term, results may remain difficult to assess: the company is loss-making, had an August earnings miss, and has a 49% estimated chance of missing its next print. Over the multi-year view, ciprocopan has China approval, US regulatory efforts are expected in 4Q2026, and the July offering extended the stated cash runway into 1H 2029.

What Nuvectis Pharma, Inc. hinges on

The thesis depends on progress toward a US marketing application for ciprocopan and on whether the Haisco pipeline expansion translates into meaningful development progress. Near-term sentiment may also be affected by company guidance, weakening jobs data, and results from Healthcare bellwethers; the evidence does not establish how these factors will resolve.